Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes.

BACKGROUND Although brain serotonin transporter (5-HTT) density has been investigated in subjects with a history of major depressive episodes (MDE), there has never been an investigation of brain 5-HTT during a current MDE. Brain 5-HTT binding potential (BP) may have an important role during MDE due to major depressive disorder, because the 5-HTT regulates extracellular 5-HT. The BP is an index of receptor density. Carbon 11-labeled 3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB) positron emission tomography (PET) is the first brain imaging technique that can measure the 5-HTT BP in cortical and subcortical brain regions in vivo. The purposes of this study were to investigate 5-HTT BP during MDE and to determine the relationship between 5-HTT BP and negativistic dysfunctional attitudes during MDE. Dysfunctional attitudes are negatively biased assumptions and beliefs regarding oneself, the world, and the future. Our recent publication of increased serotonin2 BP in MDE with severely negativistic dysfunctional attitudes suggests that this subgroup of MDE subjects has very low levels of extracellular serotonin. METHODS Regional 5-HTT BP was measured in 20 nonsmoking medication-free (> or =3 months) depressed subjects and 20 age-matched nonsmoking, medication-free, healthy subjects using [11C]DASB PET. Dysfunctional attitudes were measured using the Dysfunctional Attitudes Scale. RESULTS No difference in regional 5-HTT BP was found between MDE and healthy subjects; however, the subgroup of MDE subjects with highly negativistic dysfunctional attitudes had significantly higher 5-HTT BP compared with healthy subjects in brain regions mainly sampling serotonergic nerve terminals (prefrontal cortex, anterior cingulate, thalamus, bilateral caudate, and bilateral putamen; average, 21% greater; F(1,26), 5.6-12.2 [P values, .03-.002]). In the MDE subjects, increased 5-HTT BP was strongly associated with more negativistic dysfunctional attitudes in brain regions primarily sampling serotonergic nerve terminals (prefrontal cortex, anterior cingulate, thalamus, caudate, and putamen; r = 0.64-0.74 [P values, .003 to <.001]). CONCLUSIONS Serotonin transporters play an important role during depression. The magnitude of regional 5-HTT BP can provide a vulnerability to low levels of extracellular serotonin and symptoms of extremely negativistic dysfunctional attitudes.

[1]  Richard E Carson,et al.  Noise Reduction in the Simplified Reference Tissue Model for Neuroreceptor Functional Imaging , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Sylvain Houle,et al.  Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. , 2003, The American journal of psychiatry.

[3]  J. Oliver,et al.  The Dysfunctional Attitude Scale: Psychometric properties and relation to depression in an unselected adult population , 1985, Cognitive Therapy and Research.

[4]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[5]  Alexander Neumeister,et al.  [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder , 2000, Biological Psychiatry.

[6]  A. Rush,et al.  Cognitive biases and depression. , 1989, Journal of abnormal psychology.

[7]  B. McEwen,et al.  Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. , 1986, Archives of general psychiatry.

[8]  R. Pihl,et al.  Tryptophan depletion causes a rapid lowering of mood in normal males , 2004, Psychopharmacology.

[9]  Alan A. Wilson,et al.  Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.

[10]  C. Katona,et al.  Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides , 1990, Brain Research.

[11]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[12]  B. Jacobs,et al.  Structure and function of the brain serotonin system. , 1992, Physiological reviews.

[13]  I. Ferrier,et al.  5HT2 receptor changes in major depression , 1990, Biological Psychiatry.

[14]  V. Arango,et al.  Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. , 1990, Archives of general psychiatry.

[15]  A. Simons,et al.  The process of change in cognitive therapy and pharmacotherapy for depression. Changes in mood and cognition. , 1984, Archives of general psychiatry.

[16]  E. Leibenluft,et al.  Dysfunctional Attitudes in Borderline Personality Disorder , 1991 .

[17]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  D. Chuang,et al.  Characterization of Two [3H]Ketanserin Recognition Sites in Rat Striatum , 1987, Journal of neurochemistry.

[19]  A. Beck,et al.  Prediction of eventual suicide in psychiatric inpatients by clinical ratings of hopelessness. , 1989, Journal of consulting and clinical psychology.

[20]  Stanley J. Watson,et al.  Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide , 1997, Biological Psychiatry.

[21]  Hinako Toyama,et al.  Quantitative Analysis for Estimating Binding Potential of the Brain Serotonin Transporter with [11C]McN5652 , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  G. Aghajanian,et al.  Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. , 1990, Archives of general psychiatry.

[23]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[24]  A. Beck,et al.  Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. , 1985, The American journal of psychiatry.

[25]  M. Åsberg,et al.  5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? , 1976, Archives of general psychiatry.

[26]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[27]  E. Perry,et al.  Decreased Imipramine Binding in the Brains of Patients with Depressive Illness , 1983, British Journal of Psychiatry.

[28]  V. Arango,et al.  A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. , 2000, Archives of general psychiatry.

[29]  M. Alda,et al.  Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. , 1999, The American journal of psychiatry.

[30]  M. Fava,et al.  Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. , 1999, Journal of affective disorders.

[31]  I. Miller,et al.  Characteristics of depressed patients with elevated levels of dysfunctional cognitions , 1988, Cognitive Therapy and Research.

[32]  F. Yasuno,et al.  Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652 , 2002, Biological Psychiatry.

[33]  M. Kuhar,et al.  Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. , 1995, Journal of medicinal chemistry.

[34]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[35]  M Slifstein,et al.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  S. Houle,et al.  Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.

[37]  P A Sargent,et al.  Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. , 2000, Archives of general psychiatry.

[38]  A. Andrews,et al.  Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression , 2004, Journal of Neuroscience Methods.

[39]  F. Artigas,et al.  Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. , 1992, European journal of pharmacology.

[40]  M. Blais,et al.  A psychometric evaluation of the DSM-IV personality disorder criteria. , 1997, Journal of personality disorders.

[41]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[42]  Masanori Ichise,et al.  Modeling of Receptor Ligand Data in PET and SPECT Imaging: A Review of Major Approaches , 2001, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[43]  A. Greenshaw,et al.  A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition , 2004, Psychopharmacology.

[44]  B. Mulsant,et al.  PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. , 1999, The American journal of psychiatry.

[45]  C Burger,et al.  Requirements and implementation of a flexible kinetic modeling tool. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  C. Stockmeier,et al.  In vivo regulation of the serotonin-2 receptor in rat brain. , 1986, Life sciences.

[47]  D. Murphy,et al.  Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. , 1984, Life sciences.

[48]  Sylvain Houle,et al.  In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.

[49]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[51]  Alan A. Wilson,et al.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.

[52]  Sylvain Houle,et al.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.

[53]  T. Crow,et al.  Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides , 1984, Neuropharmacology.

[54]  Sylvain Houle,et al.  Lower dopamine transporter binding potential in striatum during depression , 2001, Neuroreport.

[55]  A. Beck,et al.  Assessment of suicidal intention: the Scale for Suicide Ideation. , 1979, Journal of consulting and clinical psychology.

[56]  D. McManus,et al.  Chronic administration of the antidepressants phenelzine, despiramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain , 1995, Cellular and Molecular Neurobiology.

[57]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[58]  M. Palkovits,et al.  5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala , 1993, Brain Research.

[59]  Bernard R. Rosner,et al.  Fundamentals of Biostatistics. , 1992 .

[60]  P. Fox,et al.  Cingulate function in depression: a potential predictor of treatment response , 1997, Neuroreport.

[61]  A. Weissman The Dysfunctional Attitude Scale: A Validation Study , 1979 .

[62]  D. Kupfer,et al.  Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.

[63]  Paul J. Harrison,et al.  β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro: Implications for Antidepressant Therapy , 2000, Neuropsychopharmacology.

[64]  J. Mann,et al.  INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS , 1983, The Lancet.

[65]  C. Bánki,et al.  Cerebrospinal fluid amine metabolites, tryptophan and clinical parameters in depression. Part 2. Psychopathological symptoms. , 1981, Journal of affective disorders.

[66]  T. Cooper,et al.  Hormone responses to fenfluramine and placebo challenge in endogenous depression , 1992, Psychiatry Research.

[67]  I. Gotlib,et al.  Factor structure of the dysfunctional attitude scale in a student population , 1986 .

[68]  Marc Laruelle,et al.  Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions , 1994 .